Clinical trial • Not applicable • Musculoskeletal
HUMAN CANCELLOUS BONE for Meniscus tear | Meniscus injury
Not applicable trial of HUMAN CANCELLOUS BONE for Meniscus tear | Meniscus injury.
Overview
- Trial Therapeutic Area
- Musculoskeletal
- Trial Disease
- Meniscus tear | Meniscus injury
- Trial Stage
- Not applicable
- Drug Modality
- Other
Key dates
- Initial CTIS Submission Date
- 23-09-2023
- First CTIS Authorization Date
- 15-03-2024
Trial design
open-label, non-operated group (patients who decide not to undergo surgery) — observational comparator (no drug comparator specified).-controlled Not applicable trial across 1 site in Germany.
- Open Label
- Yes
- Comparator
- Non-operated group (patients who decide not to undergo surgery) — observational comparator (no drug comparator specified).
- Real World Control
- Yes
- Target Sample Size
- 30
- Trial Duration For Participant
- 1825
Eligibility
Recruits 30 Vulnerable populations are not selected for this trial. Participants must be adults aged 18-60 years. Written informed consent is required from each participant (no assent process described)..
- Pregnancy Exclusion
- pregnancy (only for patients with surgery)
- Vulnerable Population
- Vulnerable populations are not selected for this trial. Participants must be adults aged 18-60 years. Written informed consent is required from each participant (no assent process described).
Inclusion criteria
- {"criterion_text":"- Partial loss of portions of the lateral meniscus and lateral joint line pain OR - Partial loss of the medial meniscus and medial joint line pain\n- Age 18-60 years\n- written consent to the study and to provide the scientific data in pseudonymized form\n- sufficient standing of the peripheral rim, so that the procedure can be performed"}
Exclusion criteria
- {"criterion_text":"- Presence of anterior cruciate ligament insufficiency that is not resolved by reconstruction of the anterior cruciate ligament within 16 weeks after partial meniscal implantation.\n- Chronic pain patients\n- inflammatory arthritis or synovitis on the treated knee\n- only for patients who will be operated: - with increased anesthesiological risk, e.g. with known or predicted difficult airway - with increased risk of bleeding - with increased risk of infection - with necrotic, infected or poorly perfused host sides - history of allergic reactions or acute hypersensitivity reactions to the IMP or any of its excipients - pregnant woman\n- Axial deviation (>2° varus or valgus)\n- realignment osteotomy not performed within 12 weeks\n- advanced cartilage damage (grade III according to ICRS) and osteoarthrosis in the affected compartment (grade III according to Kellgren and Lawrence (Kellgren and Lawrence, 1957)\n- Extension deficit of more than 3° compared to the opposite side or a knee flexion of less than 125°\n- BMI greater than 30 kg/m²\n- <18 years, >60 years\n- pregnancy (only for patients with surgery)"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Improvement of PROMs (KOOS, IKDC, VAS Pain Score) 2 and 5 years after surgery compared to scores of the non-operated group and compared to pre-surgery scores.","definition_or_measurement_approach":"Measured using patient-reported outcome measures (PROMs): IKDC, KOOS, and VAS pain score; comparison between operated and non-operated groups and comparison to pre-surgery scores at 2 and 5 years."}
Secondary endpoints
- {"endpoint_text":"- Safety of the patient: Type, frequency and severity of treatment-related AEs and SAEs","definition_or_measurement_approach":"Assessment of adverse events and serious adverse events by type, frequency and severity related to treatment."}
- {"endpoint_text":"- Efficacy of the procedure: How many patients show a progression of osteoarthrosis up to TKA?","definition_or_measurement_approach":"Number/proportion of patients progressing to osteoarthrosis requiring total knee arthroplasty (TKA) over follow-up."}
- {"endpoint_text":"- MRI evaluation: Outerbridge graduation, size of meniscus, number of patients with extrusion, size of extrusion after 6 weeks, 6 and 12 months (for operated patients) and after 2 and 5 years, comparison between the operated and the non-operated group","definition_or_measurement_approach":"MRI assessments including Outerbridge grading, meniscus size, presence and size of extrusion at specified timepoints (6 weeks, 6 and 12 months, 2 and 5 years) with operated vs non-operated group comparisons."}
- {"endpoint_text":"- Patient satisfaction: very pleased, pleased, not pleased, very unsatisfied in the operated group after 2 and 5 years","definition_or_measurement_approach":"Patient-reported satisfaction categories collected in the operated group at 2 and 5 years."}
Recruitment
- Planned Sample Size
- 30
- Recruitment Window Months
- 84
- Consent Approach
- Written informed consent required from each participant. Subject information and informed consent form available (document: Aufklarung_mit_Datenschutz_Version_4_CT_2024_03_11). Participants are adults (18-60); no assent described.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 30
Germany
- Earliest CTIS Part Ii Submission Date
- 11-03-2024
- Latest Decision Or Authorization Date
- 04-04-2025
- Processing Time Days
- 389
- Number Of Sites
- 1
- Number Of Participants
- 30
Sites
- Site Name
- Dr. Sven Behrendt, Praxis für Knie und Schulterchirugie
- Department Name
- Praxis für Knie und Schulterchirugie
- Principal Investigator Name
- Sven Behrendt
- Principal Investigator Email
- s.behrendt@dokom.net
- Contact Person Name
- Sven Behrendt
- Contact Person Email
- s.behrendt@dokom.net
- Number Of Participants
- 30
Sponsor
Primary sponsor
- Full Name
- Dr. Sven Behrendt, Knie und Schulterchirurgie
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Germany
Investigational products
- Investigational Product Name
- HUMAN CANCELLOUS BONE
- Active Substance
- HUMAN CANCELLOUS BONE
- Modality
- Other
- Routes Of Administration
- UNKNOWN USE
- Route
- UNKNOWN USE
- Authorisation Status
- No marketing authorisation (marketingAuthNumber: -)
- Maximum Dose
- 1 U unit(s)
Related trials
Other published trials that may interest you.